Status:
COMPLETED
The Effect of Green Coffee Extract on Blood Glucose Homeostasis in Healthy Adults
Lead Sponsor:
Dr. Chris McGlory, PhD
Collaborating Sponsors:
Iovate Health Sciences International Inc
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
Green coffee extract (GCE) supplementation has been shown to induce favourable health benefits on glucose metabolism and weight management. Previous literature suggests that the benefits of GCE are du...
Detailed Description
Green coffee extract (GCE) supplementation has been shown to induce favourable benefits on glucose metabolism and weight management. These effects are attributed to its high chlorogenic acid (CGA) con...
Eligibility Criteria
Inclusion
- Males and females 18-45 years
- BMI between 18.5-30 kg/m2
- No history of smoking or cardiovascular and metabolic diseases (stroke, hypertension, type II diabetes) or other diseases that could impact the study outcomes
- Weight stable (within ±2kg for 6 months)
- Generally healthy as assessed by medical and physical activity questionnaires
- No oral contraceptive use except for triphasic contraceptives
Exclusion
- Any concurrent medical, psychiatric, or orthopedic condition that, subject to investigators' discernment, would negatively affect the subject's ability to comply with the study requirements
- Any history of cardiovascular, neurological, respiratory, skeletal muscle or metabolic disease
- Using medication to manage blood glucose or lipid metabolism
- Bleeding disorders or antiplatelet/ anticoagulation therapy
- Currently using (or use within the last 3 months) monophasic or biphasic oral contraceptives
- Currently supplementing with GCE, ALA, or dihydroberberine
- Any known allergies to green coffee extract, alpha-lipoic acid, dihydroberberine or berberine, or supplementing within the last 3 months
- Currently pregnant or lactating
- Have irregular menstrual cycles (\<21 days or \>35 days)
- Any form of cancer currently or in the last 5 years
- Are recreational smokers of any form (tobacco or cannabis)
- Use of corticosteroids, testosterone replacement therapy, or any anabolic steroid
- Not willing to consume the 24-hour control diet prior to metabolic trials
- Any current Illness which could interfere with the study (e.g., prolonged diarrhea, regurgitation, etc.)
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 8 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06137066
Start Date
December 1 2023
End Date
May 8 2024
Last Update
May 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen's University
Kingston, Ontario, Canada, K7L 3N6